spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

SMI Immuno-Oncology Conference

25-27 September 2018
Copthorne Tara Hotel, London, UK

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of the field with a representation of the whole industry under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

At the SMi's Immuno-Oncology Conference participants will get:

Agenda: Valuable time is spent to discover the latest trends and hottest topics in the industry to provide the best possible agenda for our attendees. 15+ engaging presentations/case studies/keynote addresses, including:

  • Targeting immune checkpoints with Humabody VH therapeutics by James Legg of Crescendo Biologics
  • Keytruda: anticancer therapy across a wide range of malignancies by Kandeepan Ganeshalingam of Merck Sharp & Dohme Limited
  • Human tissue research in the UK: ethics and regulation by Christopher Perrett of Human Tissue Authority

Speakers: Top representation of industry leaders. 15+ leading experts in Immuno-Oncology field, including;

  • Grace Macaulay, Global Safety Physician, Patient Safety-Oncology, MedImmune
  • Harry Smith, Medical Scientist, Gilead
  • Jonathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics
  • Rochana Wickramasinghe, Evaluation Director, AstraZeneca

Workshops: Carefully selected topics for further on-sight training. 2 pre-conference workshops with in-depth knowledge on specific topics:

  • Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by LucidQuest Ventures
  • Could the Microbiome boost Cancer Immuno-Therapy - hosted by ImmuneBiotech and Lund University

Networking: Networking is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation.

To View detailed information about event programme, speaker line-up and workshop agenda visit http://www.immuno-oncology-conference.com/SMDWL 

Twitter - @SMIpharm & #immunooncologysmi

LinkedIn - SMi Pharma

CONTACT:

+44 (0)20 7827 6000

ldurneva@smi-online.co.uk

 
Print this page
Send to a friend
   
spacer
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>


News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement